News
Why Shares of Neogen Are Slumping This Week
Shares of Neogen Corporation (NASDAQ: NEOG) were down more than 16% for the week, according to data provided by S&P Global Market Intelligence. The healthcare company, which specializes in food and
Why Insulet Stock Is Sinking Today
Shares of Insulet (NASDAQ: PODD) were sinking 9.3% as of 11:27 a.m. ET on Thursday after falling as much as 11.6% earlier in the session. The decline came as investors worried about the potential
Trupanion's Membership Is Soaring. Should You Buy the Stock?
As a growth investor, few signs are as encouraging to witness from one of your holdings as a rapidly growing customer base. This is because such an occurrence typically means that the revenue of a
3 Reasons ResMed's CEO Isn't Worried About Ozempic or Wegovy
Every quarter, investors get excited for companies to report earnings. Some want the updated numbers that management teams share. Others are more curious to hear about plans and projections
Looking for Dividend Growth? Buy This Little-Known Healthcare Stock
If you consider yourself a dividend investor, asking yourself the following question may aid in your success: What separates the wheat from the chaff among dividend stocks? Such a question gets you
Is Medtronic Stock a Buy for Income Investors?
When constructing a stock portfolio oriented toward dividend growth, it is advisable to filter out all but the most proven companies as investments. One of the ways this can be done is to invest
LivaNova präsentiert Essenz In-Line Blood Monitor mit U.S. FDA 510(k)-Zulassung und CE-Prüfzeichen
LivaNova PLC (Nasdaq: LIVN), ein Marktführer im Bereich der Medizintechnik, gab heute bekannt, dass es die 510(k)-Zulassung der US-amerikanischen Food and Drug Administration (FDA) und das
Why Insulet Stock Rocked the Market Today
Medical device maker Insulet's (NASDAQ: PODD) stock was the cure for the investor blues on Wednesday. Following news of a large insider buy, the shares subsequently shot more than 6% higher on the
LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark for its Essenz™ In-Line
Why Patterson Companies Stock Dropped Today
Shares of Patterson Companies (NASDAQ: PDCO) fell as much as 14.2% early Wednesday, then partially recovered to trade down 5.6% as of 11.50 a.m. EDT after the company announced slightly
NanoString Appoints Todd Garland as Chief Commercial Officer
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for discovery and translational research, today announced that Todd Garland has been appointed Chief Commercial
Why Premier Stock Fell 16% This Week
Shares of Premier (NASDAQ: PINC) are down 15.5% this week as of 12:05 p.m. ET Friday, according to data provided by S&P Global Market Intelligence, after the healthcare-improvement leader announced
Is Medtronic Stock a Buy Now?
Companies that can withstand market volatility make for good long-term investments. Ireland-based Medtronic (NYSE: MDT), a major player in the medical device industry, has repeatedly demonstrated
3 Growth Stocks That Can Soar 50%, According to Wall Street
Analysts' price targets can help investors get an idea of whether there's a lot of bullishness surrounding a stock. But in some cases, a high upside can simply be due to elevated price targets that
Why Medtronic Stock Dropped Today
Shares of Medtronic (NYSE: MDT) fell 3.1% on Thursday, according to data provided by S&P Global Market Intelligence, giving back yesterday's post-earnings gains after it announced advisors to the
3 Dividend Stocks to Buy and Hold Until You Retire
Retirement is a big problem for many Americans. According to a recent poll from BlackRock, just 56% of people believe that they will be able to retire comfortably and have the life they want in
3 Dividend Stocks to Buy and Hold Until You Retire
Retirement is a big problem for many Americans. According to a recent poll from BlackRock, just 56% of people believe that they will be able to retire comfortably and have the life they want in
3 Massive New Markets Could Await Ozempic, And They Might Make Novo Nordisk Investors Richer
Novo Nordisk's (NYSE: NVO) molecule semaglutide is the active ingredient in its smash-hit therapies for weight loss and diabetes, which you've probably heard of under the trade names Wegovy and
Why Medtronic Stock Was a Winner Today
Tuesday was a fine day to be a Medtronic (NYSE: MDT) investor. The company's performance in its inaugural quarter of fiscal 2024 was better than expected, and the market rewarded Medtronic shares
Medtronic (MDT) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Medtronic (NYSE: MDT)Q1 2024 Earnings CallAug 22, 2023, 8:00 a.m. ET
Ryan Weispfenning
Source Fool.com
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
The healthcare sector is a hotbed of innovation, and those companies that genuinely break new ground are often handsomely rewarded, along with their shareholders. Investors looking to earn outsized
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
The healthcare sector is a hotbed of innovation, and those companies that genuinely break new ground are often handsomely rewarded, along with their shareholders. Investors looking to earn outsized
Wall Street Thinks Illumina Stock Will Rise 27% in 1 Year. Here's Why That Probably Won't Happen.
Wall Street analysts are upbeat on California-based biotech Illumina (NASDAQ: ILMN) these days, estimating on average that the stock could climb by up to 27% over the next year. But without some
Wall Street Thinks Illumina Stock Will Rise 27% in 1 Year. Here's Why That Probably Won't Happen.
Wall Street analysts are upbeat on California-based biotech Illumina (NASDAQ: ILMN) these days, estimating on average that the stock could climb by up to 27% over the next year. But without some
Wall Street Thinks Illumina Stock Will Rise 27% in 1 Year. Here's Why That Probably Won't Happen.
Wall Street analysts are upbeat on California-based biotech Illumina (NASDAQ: ILMN) these days, estimating on average that the stock could climb by up to 27% over the next year. But without some